Holocene Advisors LP Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Holocene Advisors LP grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 8.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,954,528 shares of the company’s stock after buying an additional 158,451 shares during the period. Holocene Advisors LP owned 3.56% of Vera Therapeutics worth $86,390,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Samlyn Capital LLC raised its stake in Vera Therapeutics by 90.8% during the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the last quarter. First Light Asset Management LLC increased its holdings in shares of Vera Therapeutics by 130.6% in the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the period. Vanguard Group Inc. raised its stake in shares of Vera Therapeutics by 31.5% during the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after purchasing an additional 515,106 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Vera Therapeutics during the second quarter worth $14,015,000. Finally, Logos Global Management LP grew its position in Vera Therapeutics by 65.2% in the 2nd quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock valued at $34,371,000 after buying an additional 375,000 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vera Therapeutics

In related news, Director Beth C. Seidenberg sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the transaction, the director now owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. This represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marshall Fordyce sold 23,125 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the sale, the chief executive officer now owns 307,972 shares in the company, valued at approximately $14,182,110.60. This trade represents a 6.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 89,927 shares of company stock valued at $3,800,796 over the last three months. 21.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on VERA. Wedbush raised their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Guggenheim boosted their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Finally, Scotiabank began coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $59.22.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $49.95 on Monday. The business has a 50 day moving average price of $44.21 and a 200 day moving average price of $39.77. The company has a market capitalization of $3.16 billion, a P/E ratio of -19.06 and a beta of 1.03. Vera Therapeutics, Inc. has a 1-year low of $13.09 and a 1-year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.